Liver and pancreatic injury induced by antituberculous therapy

Digestive Diseases and Sciences

Volumn 52, Issue 11, 2007, Pages 3275-3281

  Markov, M ^a   Patel, K ^a   Raeesy, A ^a   Bant, A ^a   Van Thiel, D H ^b   Nadir, A ^a,c  

^a MARICOPA MEDICAL CENTER   (United States)

^b ST LUKE S MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

Antituberculous therapy; Hepatitis; Pancreatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; ISONIAZID; PANCREAS ENZYME; PYRAZINAMIDE; PYRIDOXINE; RIFAMPICIN; STREPTOMYCIN; TRIACYLGLYCEROL LIPASE; TUBERCULOSTATIC AGENT;

ABDOMINAL PAIN; ADULT; ANAMNESIS; ARTICLE; BILE DUCT DILATATION; CASE REPORT; CHOLESTATIC HEPATITIS; CLINICAL FEATURE; DISEASE SEVERITY; DRUG WITHDRAWAL; DYSPEPSIA; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENZYME DEFECT; FEMALE; GRANULOMATOUS INFLAMMATION; HEPATOBILIARY SYSTEM; HOSPITAL DISCHARGE; HUMAN; HUMAN TISSUE; JAUNDICE; LIVER BIOPSY; LIVER FAILURE; LIVER INJURY; LYMPH NODE BIOPSY; NECROSIS; PANCREAS INJURY; PANCREATITIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RECURRENT DISEASE; SPHINCTEROTOMY; STENT; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOUS LYMPHADENITIS; VOMITING;

ADULT; ANTITUBERCULAR AGENTS; BIOPSY; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; ETHAMBUTOL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS, TOXIC; HUMANS; PANCREATITIS; PYRAZINAMIDE; RIFAMPIN; TOMOGRAPHY, X-RAY COMPUTED; TUBERCULOSIS;

EID: 34848837681     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-005-9017-9     Document Type: Article

References (58)

1. Maddrey WC, Boitnott JK (1973) Isoniazid hepatitis. Ann Intern Med 79:1-12
2. Dossing M, Wilcke JT, Askgaard DS, Nybo B (1996) Liver injury during antituberculosis treatment: an 11-year study. Tubercle Lung Dis 77:335-340
3. Mallory A, Kern F Jr (1980) Drug-induced pancreatitis: a critical review. Gastroenterology 78:813-820
4. Galan MV, Potts JA, Silverman AL, Gordon SC (2005) Hepatitis in a United States tertiary referral center. J Clin Gastroenterol 39:64-67
5. Langman MJ (1996) Drug induced pancreatitis. Gut 38:302
6. Steele MA, Burk RF, DesPrez RM (1991) Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 99:465-471
7. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK (2002) Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 166:916-919
8. Shakya R, Rao BS, Shrestha B (2004) Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann Pharmacother 38:1074-1079
9. MMWR (1993) Severe isoniazid-associated hepatitis - New York, 1991-1993. MMWR Morb Mortal Wkly Rep 42:545-547
10. Lee BH, Koh WJ, Choi MS, Suh GY, Chung MP, Kim H, Kwon OJ (2005) Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 127:1304-1311
11. Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, Pitchenik AE (1998) Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 157:1871-1876
12. Wong WM, Wu PC, Yuen MF, Cheng CC, Yew WW, Wong PC, Tam CM, Leung CC, Lai CL (2000) Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 31:201-206
13. Fernandez-Villar A, Sopena B, Vazquez R, Ulloa F, Fluiters E, Mosteiro M, Martinez-Vazquez C, Pineiro L (2003) Isoniazid hepatotoxicity among drug users: the role of hepatitis C. Clin Infect Dis 36:293-298
14. Farrell FJ, Keeffe EB, Man KM, Imperial JC, Esquivel CO (1994) Treatment of hepatic failure secondary to isoniazid hepatitis with liver transplantation. Dig Dis Sci 39:2255-2259
15. Wilmink T, Frick TW (1996) Drug-induced pancreatitis. Drug Safety 14:406-423
16. Steinberg W, Tenner S (1994) Acute pancreatitis. N Engl J Med 330:1198-1210
17. Cappell MS, Marks M (1995) Acute pancreatitis in HIV-seropositive patients: a case control study of 44 patients. Am J Med 98:243-248
18. Lankisch PG, Droge M, Gottesleben F (1995) Drug induced acute pancreatitis: incidence and severity [see Comment]. Gut 37:565-567
19. Scharer L, Smith JP (1969) Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid. Ann Intern Med 71:1113-1120
20. Ellard GA, Gammon PT (1976) Pharmacokinetics of isoniazid metabolism in man. J Pharmacokinet Biopharm 4:83-113
21. Blair IA, Mansilla Tinoco R, Brodie MJ, Clare RA, Dollery CT, Timbrell JA, Beever IA (1985) Plasma hydrazine concentrations in man after isoniazid and hydralazine administration. Hum Toxicol 4:195-202
22. Sarich TC, Youssefi M, Zhou T, Adams SP, Wall RA, Wright JM (1996) Role of hydrazine in the mechanism of isoniazid hepatotoxicity in rabbits. Arch Toxicol 70:835-840
23. Sarich TC, Zhou T, Adams SP, Bain AI, Wall RA, Wright JM (1995) A model of isoniazid-induced hepatotoxicity in rabbits. J Pharmacol Toxicol Methods 34:109-116
24. Sarich TC, Adams SP, Petricca G, Wright JM (1999) Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor. J Pharmacol Exp Ther 289:695-702
25. Jenner PJ, Ellard GA (1989) Isoniazid-related hepatotoxicity: a study of the effect of rifampicin administration on the metabolism of acetylisoniazid in man. Tubercle 70:93-101
26. Yue J, Peng RX, Yang J, Kong R, Liu J (2004) CYP2E1 mediated isoniazid-induced hepatotoxicity in rats. Acta Pharmacol Sin 25:699-704
27. Attri S, Rana SV, Vaiphei K, Sodhi CP, Katyal R, Goel RC, Nain CK, Singh K (2000) Isoniazid- and rifampicin-induced oxidative hepatic injury - protection by N-acetylcysteine. Hum Exp Toxicol 19:517-522
28. Gabriel R (1971) Rifampicin jaundice. Br Med J 3:182
29. Grosset J, Leventis S (1983) Adverse effects of rifampin. Rev Infect Dis 5(Suppl 3):S440-S450
30. Chevrel B (1971) [Rifampicin and liver]. Presse Med 79:1911-1912
31. Lee AM, Mennone JZ, Jones RC, Paul WS (2002) Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int J Tuberc Lung Dis 6:995-1000
32. (2002) Summaries for patients. Short-course treatment for latent tuberculosis is associated with more frequent liver injury than long-course treatment is. Ann Intern Med 137:I32
33. CDC (2002) From the Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. JAMA 288:2967
34. Gordin FM, Cohn DL, Matts JP, Chaisson RE, O'Brien RJ (2004) Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: Is it different than in HIV-uninfected persons? Clin Infect Dis 39:561-565
35. Bachs L, Pares A, Elena M, Piera C, Rodes J (1992) Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 102:2077-2080
36. Prince MI, Burt AD, Jones DE (2002) Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 50:436-439
37. Khokhar O, Gange C, Clement S, Lewis J (2005) Autoimmune hepatitis and thyroiditis associated with rifampin and pyrazinamide prophylaxis: an unusual reaction. Dig Dis Sci 50:207-211
38. Dutau H, Saadjian M, Bonneau V, Charpin D (2000) Unsuccessful rapid intravenous desensitization to rifampicin. Allergy 55:778-779
39. Mc DW, Ormond L, Muschenheim C, Deuschle K, Mc CR Jr, Tompsett R (1954) Pyrazinamide-isoniazid in tuberculosis. Am Rev Tuberc 69:319-333
40. Girling DJ (1982) Adverse effects of antituberculosis drugs. Drugs 23:56-74
41. Corbella X, Vadillo M, Cabellos C, Fernandez-Viladrich P, Rufi G (1995) Hypersensitivity hepatitis due to pyrazinamide. Scand J Infect Dis 27:93-94
42. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D (2003) Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 167:1472-1477
43. Gulliford M, Mackay AD, Prowse K (1986) Cholestatic jaundice caused by ethambutol. Br Med J Clin Res Ed 292:866
44. Kurokawa I, Nakahigashi Y, Teramachi M (2003) Erythema multiforme-type drug eruption due to ethambutol with eosinophilia and liver dysfunction. Int J Antimicrob Agents 21:596- 597
45. Mattson K (1973) Side effects of rifampicin. A clinical study. Scand J Respir Dis Suppl 82:1-52
46. Chan TY (1999) Isoniazid and rifampicin rarely cause acute pancreatitis in patients with tuberculosis. Int J Clin Pharmacol Ther 37:109
47. Izzedine H, Launay-Vacher V, Storme T, Deray G (2001) Acute pancreatitis induced by isoniazid. Am J Gastroenterol 96:3208-3209
48. Castro JL, Rabago LR, Vello R, Perez MD, Redondo M, Blesa C, Diaz B (2000) [Rifampicin as a cause of acute pancreatitis]. Rev Esp Enferm Dig 92:822-823
49. Mendoza JL, Larrubia JR, Lana R, Espinos D, Diaz-Rubio M (1998) [Acute pancreatitis induced by isoniazid, a casual association]. An Med Interna 15:588-590
50. Liu BA, Knowles SR, Cohen LB, Werb MR, Shear NH (1997) Pancreatic insufficiency due to antituberculous therapy. Ann Pharmacother 31:724-726
51. Perry W, Jenkins MV, Stamp TC (1979) Lysosomal enzymes and pancreatitis during rifampicin therapy. Lancet 1:492
52. Kvale PA, Parks RD (1975) Letter: Acute abdomen. An unusual reaction to isoniazid. Chest 68:271-272
53. Chan KL, Chan HS, Lui SF, Lai KN (1994) Recurrent acute pancreatitis induced by isoniazid. Tuber Lung Dis 75:383-385
54. Rabassa AA, Trey G, Shukla U, Samo T, Anand BS (1994) Isoniazid-induced acute pancreatitis. Ann Intern Med 121:433-434
55. Stephenson I, Wiselka MJ, Qualie MJ (2001) Acute pancreatitis induced by isoniazid in the treatment of tuberculosis. Am J Gastroenterol 96:2271-2272
56. Chow KM, Szeto CC, Leung CB, Li PKT (2004) Recurrent acute pancreatitis after isoniazid. Netherlands J Med 62:172-174
57. Jin C-F, Sable R (2002) Isoniazid-induced acute hepatitis and acute pancreatitis in a patient during chemoprophylaxis. J Clin Gastroenterol 35:100-101
58. Peyre CG, Wakim M, Mateo R, Genyk Y, Singh G, Selby RR, Jabbour N (2004) Unusual cases of jaundice secondary to non-neoplastic bile duct obstruction. Am Surg 70:620-624